drugset
Drugs / Mitoxantrone
last change 10 days ago re-read 8 days ago

Mitoxantrone

also known as Mitoxantrone Hydrochloride · Mitoxantrone hydrochloride liposome · DHAD · Novantrone · Lipo-MIT · Mitoxantrone Hydrochloride Liposome Injection · NSC #301739 · Mitozantrone · +14 more

Small molecule

Developed for
acute myeloid leukemia · leukemia · lymphoma · myelodysplastic syndrome · diffuse large B-cell lymphoma · prostate cancer · peripheral T-cell lymphoma, not otherwise specified · breast cancer
+85 more · non-Hodgkin lymphoma · acute lymphoblastic leukemia · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myelomonocytic leukemia M4 · adult acute monocytic leukemia · acute erythroid leukemia · acute leukemia · acute megakaryoblastic leukemia in adult · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia with t(8;21)(q22;q22) translocation · follicular lymphoma · acute myeloid leukemia, inv(16)(p13.1;q22) · childhood acute myeloid leukemia · mature T-cell and NK-cell non-Hodgkin lymphoma · acute myeloid leukemia, del(5q31-q32) · acute promyelocytic leukemia · lymphoblastic lymphoma · mantle cell lymphoma · multiple sclerosis · nasopharyngeal carcinoma · neoplasm · neuromyelitis optica · ovarian cancer · acute basophilic leukemia · acute biphenotypic leukemia · acute leukemia of ambiguous lineage · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · angioimmunoblastic T-cell lymphoma · B-cell chronic lymphocytic leukemia · Burkitt lymphoma · cancer · disease related to hematopoietic stem cell transplant · extranodal nasal NK/T cell lymphoma · hepatocellular carcinoma · HIV infectious disease · prostate adenocarcinoma · prostate neoplasm · refractory plasma cell neoplasm · T-cell prolymphocytic leukemia · acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia with t(9;11)(p22;q23) · acute myeloid leukemia, t(8;21)(q22; q22.1) · acute undifferentiated leukemia · adult acute lymphoblastic leukemia · B-cell acute lymphoblastic leukemia · childhood acute megakaryoblastic leukemia · childhood malignant neoplasm · chronic myelomonocytic leukemia · classic Hodgkin lymphoma · digestive system cancer · erythroleukemia · female breast carcinoma · gastric carcinoma · granulocytic sarcoma · head and neck cancer · Kaposi's sarcoma · metastatic prostate carcinoma · mixed phenotype acute leukemia · monocytic leukemia · myeloid leukemia · myeloid leukemia associated with down syndrome · Nodal T-follicular helper cell lymphoma, follicular type · plasma cell myeloma · primary cutaneous T-cell lymphoma · prostate carcinoma · relapsing-remitting multiple sclerosis · Richter transformation · sarcoma · secondary hemophagocytic lymphohistiocytosis · secondary progressive multiple sclerosis · small cell lung carcinoma · soft tissue sarcoma · therapy related acute myeloid leukemia and myelodysplastic syndrome · urinary bladder cancer · urothelial carcinoma · acute monocytic leukemia · acute myeloid leukemia, FLT3 internal tandem duplication · B-cell childhood acute lymphoblastic leukemia · castration-resistant prostate carcinoma · Hodgkins lymphoma · precursor B-cell acute lymphoblastic leukemia
Investigated by
National Cancer Institute (NCI) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · CSPC Ouyi Pharmaceutical Co., Ltd. · Institute of Hematology & Blood Diseases Hospital, China · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Fred Hutchinson Cancer Center
+224 more · Sun Yat-sen University · Bayer · M.D. Anderson Cancer Center · The First Affiliated Hospital with Nanjing Medical University · European Organisation for Research and Treatment of Cancer - EORTC · Memorial Sloan Kettering Cancer Center · The First Affiliated Hospital of Soochow University · University of Washington · Children's Oncology Group · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Zhejiang University · Fondazione Italiana Linfomi - ETS · Genentech, Inc. · German CLL Study Group · Lymphoma Trials Office · PETHEMA Foundation · SWOG Cancer Research Network · Technical University Dresden · Affiliated Hospital of Nantong University · Amgen · Beijing Tongren Hospital · CSPC Pharmaceutical Group Limited · Cancer and Leukemia Group B · Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte · Duke University · Eastern Cooperative Oncology Group · First Hospital of China Medical University · Fudan University · GERCOR - Multidisciplinary Oncology Cooperative Group · Huizhou Municipal Central Hospital · Lederle Laboratories · Masonic Cancer Center, University of Minnesota · Medical Research Council · Millennium Pharmaceuticals, Inc. · New York Medical College · OHSU Knight Cancer Institute · Pfizer · Rennes University Hospital · Ruijin Hospital · Rush University Medical Center · Shanghai Jiao Tong University School of Medicine · The Affiliated Hospital of Xuzhou Medical University · The Cleveland Clinic · The First Affiliated Hospital of Bengbu Medical University · The First Affiliated Hospital of Xiamen University · The First Hospital of Jilin University · Tianjin Medical University Cancer Institute and Hospital · University of Southern California · Wyeth is now a wholly owned subsidiary of Pfizer · Xuanwu Hospital, Beijing · Accelerated Community Oncology Research Network · Achieve Life Sciences · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Alliance for Clinical Trials in Oncology · Arbeitsgemeinschaft fur Internistische Onkologie · Army Medical Center of PLA · Australian and New Zealand Children's Oncology Group · BFM Austria · BFM Germany · BeiGene · Beijing Xisike Clinical Oncology Research Foundation · Biogen · CLCG France Belgium Portugal · COALL Germany · CORS Monza Italy · CPH, Czech republic · CSPC-NBP Pharmaceutical Co., Ltd. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Cancer Research Campaign Clinical Trials Centre · Cancer Research UK · Case Comprehensive Cancer Center · Central Hospital of Xiaogan · Centro di Riferimento Oncologico - Aviano · Cephalon · all 230 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed mature T-cell and NK-cell non-Hodgkin lymphoma 1 milestone
Filed China (NMPA) — mature T-cell and NK-cell non-Hodgkin lymphoma 2020-08-26

“New Drug Application for mitoxantrone hydrochloride liposome injection (new preparation) in China was submitted and accepted;” irasia.com ↗
Approved Indication not stated 2 milestones
Label expansion US (FDA) NOVANTRONE — 1996-11-13 fda.gov ↗
Approved US (FDA) NOVANTRONE — 1987-12-23 fda.gov ↗

Trials 224 · started per year

today
US approved 1987
1
2
5
4
4
3
8
10
5
8
9
3
7
5
9
9
3
3
7
3
2
4
4
2
9
6
2
3
2
7
11
16
15
14
8
8
1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 133 trials · 1 missed
Phase 1 NCT07828535 Oct 2026 → Dec 2027 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 1 NCT06651866 Dec 2024 → Dec 2026 expected acute myeloid leukemia The First Affiliated Hospital of Xiamen University Recruiting No outcome recorded
Phase 1 NCT06429449 Jul 2024 → Dec 2026 expected acute myeloid leukemia, monocytic leukemia University of Colorado, Denver Recruiting No outcome recorded
Phase 1 NCT05620862 Oct 2022 → Sep 2024 overdue childhood malignant neoplasm Sun Yat-sen University Active not recruiting No outcome recorded
Phase 1 NCT05458180 Jul 2022 → Dec 2024 peripheral T-cell lymphoma, not otherwise specified Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 1 NCT05299164 May 2022 → Dec 2023 overdue non-Hodgkin lymphoma Institute of Hematology & Blood Diseases Hospital, China Active not recruiting No outcome recorded
Phase 1 NCT05344742 Apr 2022 → Mar 2024 neoplasm CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown No outcome recorded
Phase 1 NCT05052970 Oct 2021 → Apr 2023 refractory plasma cell neoplasm CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04900766 Aug 2021 → Feb 2023 sarcoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Terminated No outcome recorded Stop: Business
Phase 1 NCT04921878 Jul 2021 → Apr 2023 cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 1/228 trials
Phase 1/2 NCT07525466 Apr 2026 → Mar 2028 expected extranodal nasal NK/T cell lymphoma, secondary hemophagocytic lymphohistiocytosis Beijing Tongren Hospital Recruiting No outcome recorded
Phase 1/2 NCT07288814 Dec 2025 → Dec 2026 expected peripheral T-cell lymphoma, not otherwise specified Sun Yat-sen University Cancer Center Not yet recruiting No outcome recorded
Phase 1/2 NCT07093710 Aug 2025 → Aug 2027 expected peripheral T-cell lymphoma, not otherwise specified Sun Yat-sen University Recruiting No outcome recorded
Phase 1/2 NCT06760039 Jan 2025 → Aug 2028 expected diffuse large B-cell lymphoma Sun Yat-sen University Recruiting No outcome recorded
Phase 1/2 NCT06594640 May 2024 → Jun 2026 overdue diffuse large B-cell lymphoma Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 1/2 NCT06224842 Dec 2023 → Dec 2024 angioimmunoblastic T-cell lymphoma Huijing Wu Unknown No outcome recorded
Phase 1/2 NCT06246162 Nov 2023 → Nov 2025 overdue plasma cell myeloma Affiliated Hospital of Nantong University Recruiting No outcome recorded
Phase 1/2 NCT05857982 May 2023 → Jan 2025 refractory plasma cell neoplasm Second Affiliated Hospital of Soochow University Unknown No outcome recorded
Phase 1/2 NCT05527275 Oct 2022 → Sep 2024 peripheral T-cell lymphoma, not otherwise specified Sun Yat-sen University Unknown No outcome recorded
Phase 1/2 NCT05522192 Jul 2022 → Nov 2025 acute myeloid leukemia Hui Zeng Unknown No outcome recorded
Phase 297 trials · 1 met primary
Phase 2 NCT07831395 Sep 2026 → Dec 2030 expected Richter transformation Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT07372352 Jan 2026 → Jan 2028 expected peripheral T-cell lymphoma, not otherwise specified The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2 NCT07108530 Aug 2025 → Aug 2027 expected acute myeloid leukemia Shanxi Bethune Hospital Recruiting No outcome recorded
Phase 2 NCT07168317 Aug 2025 → Aug 2028 expected angioimmunoblastic T-cell lymphoma The Affiliated Hospital of Xuzhou Medical University Recruiting No outcome recorded
Phase 2 NCT06921044 Apr 2025 → Feb 2026 overdue diffuse large B-cell lymphoma Xiaohui He Not yet recruiting No outcome recorded
Phase 2 NCT06892431 Apr → Dec 2025 overdue nasopharyngeal carcinoma Shanghai JMT-Bio Inc. Not yet recruiting No outcome recorded
Phase 2 NCT06761417 Jan 2025 → Apr 2027 expected cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 2 NCT06475287 Jul 2024 → Jul 2025 overdue hepatocellular carcinoma Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT06472713 Jul 2024 → Oct 2025 overdue nasopharyngeal carcinoma Ming-Yuan Chen Recruiting No outcome recorded
Phase 2 NCT06621199 Jul 2024 → Dec 2027 expected acute myeloid leukemia First Affiliated Hospital of Zhejiang University Recruiting No outcome recorded
Phase 2/33 trials
Phase 2/3 NCT05739630 Jan 2023 → Jan 2024 acute leukemia The First Affiliated Hospital of Soochow University Unknown No outcome recorded
Phase 2/3 NCT03258320 Jan 2015 → Dec 2026 expected prostate cancer Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
Phase 2/3 NCT00004071 Aug 1999 → Sep 2007 prostate cancer Pfizer Completed No outcome recorded
Phase 337 trials · 4 met primary · 6 missed
Phase 3 NCT07639879 Jul 2026 → Jul 2029 expected mature T-cell and NK-cell non-Hodgkin lymphoma Tarapeutics Science Inc. Not yet recruiting No outcome recorded
Phase 3 NCT06345365 Jan 2024 → Dec 2026 expected acute myeloid leukemia Zhongnan Hospital Recruiting No outcome recorded
Phase 3 NCT05717764 Feb 2023 → Sep 2026 overdue nasopharyngeal carcinoma CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT04486391 Dec 2020 → Oct 2025 classic Hodgkin lymphoma BeiGene Terminated No outcome recorded Stop: Business
Phase 3 NCT03504410 Nov 2018 → Oct 2021 acute myeloid leukemia Cornerstone Pharmaceuticals Terminated Missed primary
Phase 3 NCT02521493 Dec 2015 → Jun 2024 overdue Down syndrome, myelodysplastic syndrome, myeloid leukemia associated with down syndrome Children's Oncology Group Active not recruiting No outcome recorded
Phase 3 NCT02461537 Sep 2015 → Apr 2022 acute myeloid leukemia DKMS Completed Missed primary
Phase 3 NCT02072811 Feb 2014 → Feb 2018 acute myeloid leukemia dr hab. n. med. Agnieszka Wierzbowska Unknown No outcome recorded
Phase 3 NCT01828489 Mar 2013 → Mar 2018 childhood acute myeloid leukemia Vastra Gotaland Region Unknown No outcome recorded
Phase 3 NCT02937285 Dec 2010 → May 2020 multiple sclerosis Rennes University Hospital Completed No outcome recorded
Phase 410 trials · 1 missed
Phase 4 NCT07354698 Feb 2026 → Feb 2028 expected thyroid gland papillary carcinoma Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Not yet recruiting No outcome recorded
Phase 4 NCT02021825 Mar 2009 → Dec 2014 neuromyelitis optica Xuanwu Hospital, Beijing Unknown No outcome recorded
Phase 4 NCT00408278 Jul 2005 → Apr 2012 acute promyelocytic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00180167 Jan 2005 → Jul 2010 acute myeloid leukemia Technical University Dresden Completed No outcome recorded
Phase 4 NCT00180102 Dec 2003 → Nov 2009 acute myeloid leukemia Technical University Dresden Completed Missed primary
Phase 4 NCT00853008 Jan 2003 → Nov 2012 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00304291 Aug 2001 → May 2004 CNS demyelinating autoimmune disease, autoimmune disorder of the nervous system, neuromyelitis optica, transverse myelitis State University of New York at Buffalo Completed No outcome recorded
Phase 4 NCT00180128 Jan 2000 → Nov 2012 acute promyelocytic leukemia Technical University Dresden Unknown No outcome recorded
Phase 4 NCT00526305 Jan 2000 → Apr 2005 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00199069 Apr 1993 → Jan 1999 adult acute lymphoblastic leukemia Goethe University Completed No outcome recorded
Phase not applicable16 trials · 1 missed
— NCT07490288 May → Jul 2026 overdue acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT07389356 Feb 2026 → Oct 2027 expected diffuse large B-cell lymphoma The First Affiliated Hospital with Nanjing Medical University Not yet recruiting No outcome recorded
— NCT06758726 Dec 2024 → Oct 2026 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
— NCT06329999 Feb 2024 → Dec 2025 overdue acute myeloid leukemia, myelodysplastic syndrome Ruijin Hospital Recruiting No outcome recorded
— NCT06211881 Oct 2023 → Sep 2025 mature T-cell and NK-cell non-Hodgkin lymphoma The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded
— NCT05990985 Sep 2023 → Aug 2024 overdue diffuse large B-cell lymphoma The First Hospital of Jilin University Not yet recruiting No outcome recorded
— NCT05941585 Aug 2023 → Jan 2025 acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Completed No outcome recorded
— NCT05814718 Apr 2023 → Dec 2025 disease related to hematopoietic stem cell transplant First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
— NCT05814731 Apr 2023 → Dec 2025 disease related to hematopoietic stem cell transplant First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
— NCT05772728 Apr → Dec 2023 Nodal T-follicular helper cell lymphoma, follicular type The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded
Comparator or background therapy145 trials
Phase 0 NCT06499025 Background Feb 2024 → Dec 2026 expected acute myeloid leukemia with t(8;21)(q22;q22) translocation BGI, China Enrolling by invitation No outcome recorded
Phase 1 NCT06007911 Background Aug 2024 → Dec 2025 acute myeloid leukemia Medical College of Wisconsin Withdrawn No outcome recorded
Phase 1 NCT05330377 Background Mar 2023 → May 2027 acute myeloid leukemia Ayman H Qasrawi Withdrawn No outcome recorded Stop: Business
Phase 1 NCT03983824 Background May 2020 → Jun 2027 expected acute myeloid leukemia National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT03735446 Background Jan → Mar 2019 acute myeloid leukemia, myelodysplastic syndrome Dana-Farber Cancer Institute Terminated No outcome recorded Stop: Business
Show all 145 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 5

DateIssuerRelease
2022-08-18 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Regulatory VOLUNTARY ANNOUNCEMENT - DUOENDA (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS irasia.com ↗
2022-01-11 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Regulatory VOLUNTARY ANNOUNCEMENT - "MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION" OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
2016-12-04 Karyopharm Therapeutics Inc Results Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting karyopharm.com ↗
In this study, the combination of selinexor with high-dose cytarabine (HiDAC) and mitoxantrone is feasible and tolerable and the recommended phase 2 dose was identified as selinexor 80mg per day plus HiDAC and mitoxantrone.
2008-04-10 Teva Branded Pharmaceutical Products R&D, Inc. Results Copaxone® Significantly Reduced Annual Relapse Rates And Stabilized Disease Progression In Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment tevapharm.com ↗
In those who switched to mitoxantrone, the annualized decreased rate was reduced by 71 percent (0.53 to 0.15) ( p=0.64).
2006-04-12 Teva Branded Pharmaceutical Products R&D, Inc. Regulatory Teva Announces Approval of Mitoxantrone Hydrochloride Injection USP tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Mitoxantrone Hydrochloride Injection USP, 2 mg/mL.

All press releases naming this drug 16 releases

DateIssuerRelease

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 374 sources stand behind the page.

FieldValueCited text
Known as mitoxantrone “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗
338

“Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With...” NCT00180167 ↗

“An Open-label, Multi-center, Phase 2 Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Subjects With Relapsed Small-cell Lung Cancer After...” NCT04352413 ↗

“Investigator's choice treatment with chidamide, golidocitinib, mitoxantrone hydrochloride liposome, or gemcitabine hydrochloride administered according to the respective...” NCT07639879 ↗

“Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.” NCT06651866 ↗

“High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).” NCT02920008 ↗

“* EA±Mitox regimen: etoposide injection 100 mg/m2, cytarabine injection 100-150 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).” NCT06387069 ↗

“Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.” NCT05681403 ↗

“high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)” NCT01587430 ↗

“Participants on mitoxantrone, etoposide, cytarabine(MEC) will receive 8 mg/m\^2 of mitoxantrone daily by IV for 3 days (day 1 to 3)” NCT05876832 ↗

“haM Cytarabine 1 g/m2 every 12 hours for 3 days; Mitoxantrone 10 mg/m2 days 4 and 5, intrathecal cytarabine days 6 and 15.” NCT06211452 ↗

Show 328 more sources
Known as DHAD “addition of cyclosporine (CYSP) to mitoxantrone (DHAD) and etoposide (VP-16)” NCT00002688 ↗
5

“mitoxantrone (DHAD) IV over 30 minutes” NCT00002531 ↗

“DHAD Mitoxantrone, NSC-301739” NCT00002576 ↗

“DHAD Mitoxantrone, NSC-301739” NCT00002565 ↗

“DHAD Mitoxantrone, NSC-301739” NCT00002549 ↗

“DHAD Mitoxantrone” NCT00002674 ↗
Known as Doxorubicin “Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.” NCT06651866 ↗
Known as Lipo-MIT “PURPOSE: This trial aimed to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection (Lipo-MIT) in advanced breast cancer (ABC).” PMID 34633576 ↗ Oct 2021
3

“mitoxantrone hydrochloride liposome (Lipo-MIT) plus cyclophosphamide, vincristine, etoposide, and prednisone (COEP) in untreated PTCL.” PMID 40292284 ↗ Apr 2025

“Mitoxantrone hydrochloride liposome (Lipo-MIT) has shown clinical benefits in various tumors.” PMID 40232151 ↗ Apr 2025

“Mitoxantrone Hydrochloride Liposome(Lipo-MIT)” NCT07372352 ↗
Known as liposomal formulation of mitoxantrone “CSPC Pharmaceutical Group has developed the liposomal formulation of mitoxantrone” NCT06220097 ↗
Known as liposomal mitoxantrone “In the pivotal phase II study of liposomal mitoxantrone” NCT06220097 ↗
Known as Liposomal mitoxantrone hydrochloride “Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.” NCT04509466 ↗
Known as MITO “Mitoxantrone (MITO, Novantrone®), a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, has been shown to...” NCT00304291 ↗
Known as Mitoxantrone (Novantrone) “Mitoxantrone (Novantrone)” NCT01513603 ↗
Known as mitoxantrone HCL “Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL (Novantrone) and a combination of lyophilized lipids.” NCT00024492 ↗
Known as Mitoxantrone Hydrochloride “Mitoxantrone hydrochloride, a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis, has been...” PMID 16831964 ↗ Jul 2006
51

“An Open-label, Multi-center, Phase 2 Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Subjects With Relapsed Small-cell Lung Cancer After...” NCT04352413 ↗

“A Single-arm, Open-label, Single-center Phase Ib Study to Evaluate the Safety and Efficacy of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Advanced...” NCT04331743 ↗

“M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine” NCT02520011 ↗

“To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.” NCT00002259 ↗

“Mitoxantrone Hydrochloride was given at a dose of 12mg/m\^2/day I.V. on days 1, 2, and 3.” NCT00268242 ↗

“Patients receive mitoxantrone hydrochloride IV over 5 minutes once a week for 3 weeks.” NCT00627354 ↗

“Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)” NCT05941585 ↗

“mitoxantrone hydrochloride IV over 1 hour” NCT00550992 ↗

“Mitoxantrone hydrochloride ( Novantrone )” NCT00002003 ↗

“Drug: Mitoxantrone Hydrochloride” NCT03012672 ↗

Show 41 more sources
Known as Mitoxantrone hydrochloride liposome “This is a multicenter, randomized, open-label, phase Ib study to evaluate the safety, efficacy and pharmacokinetic characteristics of Mitoxantrone Hydrochloride Liposome in...” NCT04719065 ↗
6

“This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with recurrent/metastatic...” NCT04902027 ↗

“mitoxantrone hydrochloride liposome (Lipo-MIT) plus cyclophosphamide, vincristine, etoposide, and prednisone (COEP) in untreated PTCL.” PMID 40292284 ↗ Apr 2025

“Mitoxantrone Hydrochloride Liposome is a liposomal formulation of the anthracenedione chemotherapy agent mitoxantrone.” NCT07372352 ↗

“Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 3 weeks” NCT06433362 ↗

“All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).” NCT04718376 ↗

“Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1” NCT06345365 ↗
Known as Mitoxantrone Hydrochloride Liposome Injection “PURPOSE: This trial aimed to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection (Lipo-MIT) in advanced breast cancer (ABC).” PMID 34633576 ↗ Oct 2021
2

“A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers” NCT04902027 ↗

“M: Mitoxantrone Hydrochloride Liposome Injection: 15 mg/m², IV, on Day 1, every 4 weeks (q4w)” NCT06741722 ↗
Known as mitoxantrone liposome hydrochloride “The recommended dose of mitoxantrone liposome hydrochloride is not limited.” NCT06220097 ↗
Known as Mitozantrone ClinicalTrials.gov intervention name — accepted as the source's own label NCT00100477 ↗
1

NCT00079482 ↗
Known as MTX “Mitoxantrone (MTX): 3g/m2, i.v., in 24 hours, day 1, 28 and 56.” NCT00526305 ↗
Known as Novantrone “Mitoxantrone (MITO, Novantrone®), a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, has been shown to...” NCT00304291 ↗
5

“Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL (Novantrone) and a combination of lyophilized lipids.” NCT00024492 ↗

“To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.” NCT00002259 ↗

“Mitoxantrone hydrochloride ( Novantrone )” NCT00002003 ↗

“Mitoxantrone (Novantrone)” NCT00059631 ↗

NCT00577993 ↗
Known as Novantrone(R) “Novantrone(R) (Mitoxantrone)” NCT00002003 ↗
Known as NSC #301739 “A Phase II Trial of Adjuvant Mitoxantrone (NSC #301739) for High Risk Patients Following Radical Prostatectomy” NCT00003858 ↗
2

“DHAD Mitoxantrone, NSC-301739” NCT00002565 ↗

“DHAD Mitoxantrone, NSC-301739” NCT00002576 ↗
Known as NSC-290193 “NSC-290193 DHAD Mitoxantrone” NCT00002688 ↗
Known as PLM60 “An Open-label, Multi-center, Phase 2 Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Subjects With Relapsed Small-cell Lung Cancer After...” NCT04352413 ↗
1

“PLM60” NCT04331743 ↗
Known as plm60-s “Plm60-s is a pegylated liposomal mitoxantrone formulation, in which mitoxantrone was loaded into small unilamellar vesicles (~60 nm) made from solid lipid membrane.” PMID 25034977 ↗ Jul 2014
Known as Ralenova (Mitoxantrone) “Ralenova® (Mitoxantrone)” NCT01627938 ↗
Action Inhibit “Mitoxantrone is used to treat bone pain in advanced prostate cancer and inhibits many proteins that the cancer cells need to multiply.” NCT00059631 ↗
Modality Small molecule “a synthetic anthracenedione” NCT00304291 ↗